Systemic corticosteroids for the outpatient treatment of necrobiosis lipoidica in a diabetic patient

被引:13
|
作者
Tan, Eunice
Patel, Vinod
Berth-Jones, John
机构
[1] Addenbrookes Hosp NHS Trust, Dept Dermatol, Cambridge CB2 2QQ, England
[2] George Eliot Hosp NHS Trust, Dept Med, Nuneaton, Warwick, England
[3] George Eliot Hosp NHS Trust, Dept Dermatol, Nuneaton, Warwick, England
关键词
activated protein C resistance; antiseptic dressings; becaplermin gel; insulin-dependent diabetes mellitus; systemic corticosteroids; ulcerated necrobiosis lipoidica;
D O I
10.1080/09546630701308294
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Necrobiosis lipoidica (NL) remains a major therapeutic challenge for the dermatologist and diabetologist. Amongst many treatment modalities attempted, systemic corticosteroids remain controversial, not least because a proportion of NL patients are diabetic, and corticosteroids are likely to destabilize their diabetic control. Close supervision as an inpatient is often required. We report the ambulatory outpatient management of an insulin-dependent diabetic with ulcerated necrobiosis lipoidica complicated by activated protein C resistance.
引用
收藏
页码:246 / 248
页数:3
相关论文
共 50 条
  • [21] Comorbidities and diabetic complications in patients with necrobiosis lipoidica
    Severson, Kevin J.
    Patel, Meera H.
    Brumfiel, Caitlin M.
    Breen, Ilana
    Butterfield, Richard J.
    Nelson, Steven A.
    Sekulic, Aleksander
    Pittel-kow, Mark R.
    Mangold, Aaron R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (04) : 891 - 894
  • [22] Ulcerated necrobiosis lipoidica in a patient with insulin-dependent diabetes - Beneficial effect of oral corticosteroids
    Hocqueloux, L
    Gautier, JF
    Lebbe, C
    Jellal, M
    Vexiau, P
    Morel, P
    Cathelineau, G
    PRESSE MEDICALE, 1996, 25 (01): : 25 - 27
  • [23] NECROBIOSIS LIPOIDICA DIABETICORUM IN A JUVENILE DIABETIC - TREATMENT BY EXCISION AND SKIN-GRAFTING
    MARR, TJ
    TRAISMAN, HS
    GRIFFITH, BH
    SCHAFER, MA
    CUTIS, 1977, 19 (03): : 348 - 350
  • [24] Thalidomide for the treatment of refractory necrobiosis Lipoidica
    Kukreja, T
    Petersen, J
    ARCHIVES OF DERMATOLOGY, 2006, 142 (01) : 20 - 22
  • [25] FIBRINOLYTIC AGENTS IN TREATMENT OF NECROBIOSIS LIPOIDICA
    RHODES, EL
    BRITISH JOURNAL OF DERMATOLOGY, 1976, 95 (06) : 673 - 674
  • [26] FIBRINOLYTIC AGENTS IN TREATMENT OF NECROBIOSIS LIPOIDICA
    RHODES, EL
    ANGIOLOGY, 1978, 29 (01) : 60 - 64
  • [27] Topical Ruxolitinib in the Treatment of Necrobiosis Lipoidica
    Hwang, Angelina
    Kechter, Jacob
    Li, Xing
    Bhullar, Puneet
    Boudreaux, Blake
    Severson, Kevin
    Hughes, Alysia
    Branch, Emily
    Sekulic, Aleksandar
    Pittelkow, Mark
    Mangold, Aaron
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB239 - AB239
  • [28] Tretinoin treatment of necrobiosis lipoidica diabeticorum
    Boyd, AS
    DIABETES CARE, 1999, 22 (10) : 1753 - 1754
  • [29] Cyclosporin A in the treatment of necrobiosis lipoidica diabeticorum
    DArgento, V
    Curatoli, G
    Filotico, R
    Foti, C
    Vena, GA
    JOURNAL OF DERMATOLOGICAL TREATMENT, 1997, 8 (02) : 123 - 125
  • [30] Intralesional etanercept for the treatment of necrobiosis lipoidica
    Zeichner, J
    Stern, D
    Lebwohl, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB57 - AB57